首页> 美国卫生研究院文献>OncoTargets and therapy >Primary Resistance to Brigatinib in a Patient with Lung Adenocarcinoma Harboring ALK G1202R Mutation and LIPI-NTRK1 Rearrangement

【2h】

Primary Resistance to Brigatinib in a Patient with Lung Adenocarcinoma Harboring ALK G1202R Mutation and LIPI-NTRK1 Rearrangement

机译：肺腺癌患者患有肺腺癌患者的初期抗性患者涉及ALK G1202R突变和Lipi-NTRK1重排

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

期刊名称 OncoTargets and therapy
作者
Zhiwei Xiao; Xuewu Huang; Biyuan Xie; Wenzhuan Xie; Mengli Huang; Lizhu Lin;
展开▼
作者单位

展开▼
年(卷),期 2020(-1),-1
年度 2020
页码 -1
总页数 5
原文格式 PDF
正文语种
中图分类应用微生物学;肿瘤学;
关键词

机译：NTRK1;ALK;初级抵抗;Brigatinib;NSCLC;

相似文献

外文文献
中文文献
专利

1. Primary Resistance to Brigatinib in a Patient with Lung Adenocarcinoma Harboring ALK G1202R Mutation and LIPI-NTRK1 Rearrangement [J] . Zhiwei Xiao, Xuewu Huang, Biyuan Xie, OncoTargets and therapy . 2020,第2期

机译：肺腺癌患者患有肺腺癌患者的初期抗性患者，涉及ALK G1202R突变和Lipi-NTRK1重排
2. A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib [J] . Sharma Geeta G., Cortinovis Diego, Agustoni Francesco, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2019,第11期

机译：具有AlK阳性肺癌的患者的化合物L1196M / G1202R Alk突变与Brigatinib的获得性抗性也赋予Lorlatinib的常规抗性
3. Dramatic Response to Lorlatinib in a Heavily Pretreated Lung Adenocarcinoma Patient Harboring G1202R Mutation and a Synchronous Novel R1192P ALK Point Mutation [J] . Sara Baglivo, Biagio Ricciuti, Vienna Ludovini, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2018,第8期

机译：对Lorlatinib在含G1202R突变的重预处理肺腺癌患者中的戏剧反应和同步新的R1192P ALK点突变
4. EGFR Mutations in Lung Adenocarcinoma: Correlation with F-18 FDG PET/CT [C] . Jinyoung Yoo, Sonya Youngju Park International Molecular Medicine Tri-Conference. . 2016

机译：肺腺癌的EGFR突变：与F-18 FDG PET / CT的相关性
5. Pharmacology Profiles of ALK and FLT3 Kinase Inhibitors against Non-Small-Cell Lung Cancer Cells and Acute Myeloid Leukemia Cells with Cancer Driver Mutations [D] . 森政道 2019

机译：ALK和FLT3激酶抑制剂对非小细胞肺癌细胞和急性髓系白血病细胞的癌症驱动突变的药理作用
6. Responses to crizotinib and chemotherapy in patients with lung adenocarcinoma harboring a concomitant EGFR mutation and ALK gene rearrangement: A case report and review of the literature [O] . Yuping Li, Shanshan Su, Guoping Cai, -1

机译：伴有EGFR突变和ALK基因重排的肺腺癌患者对克唑替尼和化疗的反应：1例病例并文献复习
7. Next-Generation Sequencing Reveals a Novel NSCLC ALK F1174V Mutation and Confirms ALK G1202R Mutation Confers High-Level Resistance to Alectinib (CH5424802/RO5424802) in ALK-Rearranged NSCLC Patients Who Progressed on Crizotinib [O] . Ou Sai-Hong Ignatius, Azada Michele, Hsiang David J., 2014

机译：下一代测序揭示了一种新型NSCLC ALK F1174V突变，并确认ALK G1202R突变赋予在ALK重排的克唑替尼治疗的NSCLC患者中对Alectinib（CH5424802 / RO5424802）的高水平耐药性

Primary Resistance to Brigatinib in a Patient with Lung Adenocarcinoma Harboring ALK G1202R Mutation and LIPI-NTRK1 Rearrangement

著录项

相似文献

相关主题

期刊订阅